小児におけるファーストジェネレーションINSTI耐性HIV患者へのドルテグラビル投与量選択のためのモデル導入
Hardik Chandasana1, Ann M Buchanan2, Cassidy A Henegar3
1From theClinical Pharmacology Modeling Simulation, GSK, Collegeville, PA.
Abstract:
Twice-daily dosing of Dolutegravir is approved for adults with HIV and integrase strand transfer inhibitor resistance, but not for children. Population pharmacokinetic modeling and simulations identified a weight-tiered twice-daily dose for children, predicted to yield dolutegravir exposures within the therapeutic window and provide similar efficacy and safety as seen in adults with HIV-1 and first-generation integrase strand transfer inhibitor resistance.
さらに関連する動画
04:55Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
関連する概念動画
Dose-Response Relationship: Selectivity and Specificity
Antibiotic Selection
What is Natural Selection?
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Dose Size and Dosing Frequency: Determination Methods
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
